Document is current
Any future updates will be listed below
-
Authors
Camargo, Lucas
Gianlorenço, Anna Carolyna
Pacheco-Barrios, Kevin
Pichardo, Elly
Costa, Valton
Choi, Hyuk
Song, Jae-Jun
Fregni, Felipe
-
Funding
Funding for this research was provided by:
Neurive
- License Information
-
More Information
Article History
Received: 27 March 2025
Accepted: 27 August 2025
First Online: 3 October 2025
Declarations
:
: HC and JS are affiliated with neuromodulation company Neurive Co. This company develops neuromodulation technology (e.g., taVNS) to treat common brain disorders. FF is funded by a research grant from Neurive to Spaulding Rehabilitation Hospital. The other authors declare no conflict of interest.
: This trial (Protocol number: 2022P003200) was approved by the Mass General Brigham Human Research Committee. The clinical trial was first posted on 06/04/2023 (NCT05801809), and before the study began, all participants provided their consent by signing an online informed consent form via the secure REDCap web platform. The study was conducted in compliance with the Declaration of Helsinki.
